Cunha-Silva_2022_Medicine.(Baltimore)_101_e30315

Reference

Title : 15-Year progression to liver cancer in the lack of treatment for lysosomal acid lipase deficiency: A case report - Cunha-Silva_2022_Medicine.(Baltimore)_101_e30315
Author(s) : Cunha-Silva M , de Franca EVC , Veiga CT , Greca RD , de Moraes PBS , de Campos Mazo DF , de Ataide EC , Perales SR , Monici LT , Seva-Pereira T
Ref : Medicine (Baltimore) , 101 :e30315 , 2022
Abstract :

RATIONALE: Lysosomal acid lipase deficiency (LAL-D) is a poorly diagnosed genetic disorder characterized by the accumulation of cholesteryl esters and triglycerides in many tissues, leading to dyslipidemia and cardiovascular complications. In the liver, deposits are found within hepatocytes and Kupffer cells, generating microvesicular steatosis, progressive fibrosis, and cirrhosis. Sebelipase alfa is the target therapy which can improve laboratory changes and reduce the progression of liver damage, but this is not yet widely available. PATIENT CONCERNS: We are reporting a 15-year follow-up of a Brazilian man who was diagnosed with cirrhosis at age 43 and with LAL-D at age 53, but he has never been treated with sebelipase alfa for economic reasons. During the coronavirus disease 2019 (COVID-19) pandemic, he lost follow-up and missed three 6-month ultrasound exams for liver cancer screening. DIAGNOSIS: At age 58, a remarkable deterioration in liver function was observed and he was diagnosed with hepatocellular carcinoma (HCC) outside the Milan Criteria (two nodules measuring 48mm and 25mm). Three other individuals with LAL-D and progression to liver cancer have been reported so far and none of them underwent enzyme replacement therapy: an 11-year-old girl with HCC, a 51-year-old male with cholangiocarcinoma, and a 21-year-old male with hepatocellular-cholangiocarcinoma. The latter had the same mutation in the gene LIPA as our patient, but a relationship between this variant and malignancies has not yet been established. LESSONS: We emphasize how important is to treat LAL-D patients after diagnosis in order to avoid worsening liver function and progression to neoplasms. Untreated individuals should be considered at a higher risk but the most appropriate liver cancer screening program for this subgroup is still unknown.

PubMedSearch : Cunha-Silva_2022_Medicine.(Baltimore)_101_e30315
PubMedID: 36107601
Gene_locus related to this paper: human-LIPA

Citations formats

Cunha-Silva M, de Franca EVC, Veiga CT, Greca RD, de Moraes PBS, de Campos Mazo DF, de Ataide EC, Perales SR, Monici LT, Seva-Pereira T (2022)
15-Year progression to liver cancer in the lack of treatment for lysosomal acid lipase deficiency: A case report
Medicine (Baltimore) 101 :e30315

Cunha-Silva M, de Franca EVC, Veiga CT, Greca RD, de Moraes PBS, de Campos Mazo DF, de Ataide EC, Perales SR, Monici LT, Seva-Pereira T (2022)
Medicine (Baltimore) 101 :e30315